Neurofibromatosis Type 2 Genetic Test: NF2 Gene Mutations and Results

An NF2 genetic test looks for disease-causing changes in the NF2 gene, which can predispose a person to vestibular schwannomas, meningiomas, spinal tumors, peripheral nerve schwannomas, and certain eye findings. The condition was historically called neurofibromatosis type 2, but current medical terminology is NF2-related schwannomatosis. Testing may confirm a suspected diagnosis, clarify risk in a child or adult with suggestive tumors, identify relatives who need surveillance, or investigate a tumor pattern that does not fit a simple sporadic explanation. Interpretation is not always straightforward: many affected people have a constitutional variant detectable in blood, while others have mosaic disease that may require high-depth testing or analysis of more than one tumor. A positive result can guide surveillance and family testing, but a negative blood test does not always exclude NF2-related schwannomatosis. Results are most useful when reviewed alongside age, tumor type and location, hearing history, eye findings, family history, and the laboratory methods used.

• NF2-related schwannomatosis is distinct from neurofibromatosis type 1 and has a different gene, tumor spectrum, and surveillance plan.
• Testing usually includes NF2 sequencing plus deletion-and-duplication analysis, with methods designed to detect low-level mosaic variants when appropriate.
• A pathogenic variant found in blood or saliva can confirm constitutional disease, but tumor testing may be essential when blood testing is negative.
• A variant found in only one tumor does not automatically prove an inherited or body-wide condition.
• Results can affect hearing surveillance, brain and spine imaging, eye care, treatment choices, testing of relatives, and reproductive planning.

Table of Contents

• What NF2-Related Schwannomatosis Means
• When an NF2 Genetic Test Is Considered
• How NF2 Testing Detects Germline and Mosaic Disease
• How to Interpret Positive, Negative, and Uncertain Results
• Distinguishing NF2 From Other Schwannomatosis Conditions
• Surveillance After an NF2 Diagnosis
• How Results Influence Treatment and Hearing Care
• Family Testing, Inheritance, and Reproductive Options

What NF2-Related Schwannomatosis Means

NF2-related schwannomatosis is a tumor-predisposition condition caused by a pathogenic variant in the NF2 gene. The gene provides instructions for merlin, also called schwannomin, a protein that helps regulate cell growth and contact between cells. When both working copies of NF2 are lost or inactivated within a susceptible cell, that cell can grow into a tumor. This “two-hit” mechanism helps explain why a person can inherit or develop one altered copy throughout some or all of the body, while individual tumors acquire an additional change later.

The classic feature is a vestibular schwannoma affecting each side. These tumors arise along the vestibular portion of the eighth cranial nerve and may cause hearing loss, tinnitus, imbalance, or pressure-related symptoms. The condition can also cause meningiomas, ependymomas, schwannomas of other cranial or peripheral nerves, and spinal tumors. Eye findings may include juvenile cataracts and retinal abnormalities. Some children first present with a skin schwannoma, a focal nerve palsy, weakness, or an eye finding rather than hearing symptoms.

The modern name matters. “Neurofibromatosis type 2” can suggest that the condition is simply a second form of NF1, but the two disorders are biologically and clinically different. NF1 is caused by the NF1 gene and is commonly associated with café-au-lait macules, freckling, neurofibromas, and optic pathway gliomas. NF2-related schwannomatosis centers on schwannomas, meningiomas, ependymomas, hearing risk, and specific ocular findings. A comparison with NF1 genetic testing can be useful when a referral uses the broad word “neurofibromatosis” without specifying the suspected condition.

Severity varies widely. Some people develop multiple tumors and hearing impairment at a young age, while others—especially some people with mosaic disease—have fewer tumors or later onset. Truncating variants are associated on average with more severe disease, but genotype is not a precise forecast. Tumor location, growth, mosaic distribution, and individual biology all affect outcome.

When an NF2 Genetic Test Is Considered

Testing is considered when a person’s clinical or tumor history raises the possibility of NF2-related schwannomatosis. Bilateral vestibular schwannomas are strongly suggestive, particularly in a younger person. Other reasons include a unilateral vestibular schwannoma plus additional schwannomas or meningiomas, multiple meningiomas, a combination of cranial and spinal tumors, characteristic eye findings, or a close relative with a confirmed diagnosis. The younger the age at which a vestibular schwannoma or multiple relevant tumors appear, the more important it is to consider an inherited or mosaic predisposition.

Modern diagnostic criteria combine clinical findings, family history, and molecular evidence. A diagnosis may be established through a characteristic tumor pattern, a pathogenic NF2 variant found constitutionally, or the same pathogenic NF2 variant identified in two anatomically distinct NF2-associated tumors. This integrated approach is especially important for mosaic disease, in which the variant may be absent from routine blood testing or present at a level below a laboratory’s reporting threshold.

Testing can also be appropriate after tumor sequencing. An NF2 alteration is common in individual sporadic schwannomas and meningiomas, so a tumor result must be interpreted carefully. One tumor containing two NF2 hits may reflect changes limited to that tumor. It becomes more suggestive of mosaic NF2-related schwannomatosis when the same initiating pathogenic variant is found in two separate tumors, or when a low-level matching variant is detected in blood, saliva, or another non-tumor sample.

Children and adolescents may be referred because of a juvenile cataract, retinal finding, unexplained mononeuropathy, facial weakness, a skin or peripheral schwannoma, or a family history. Predictive testing in a minor can be medically useful when a familial pathogenic variant is known because surveillance may begin before adulthood. This differs from testing a child for an adult-onset condition with no childhood intervention.

Before testing, the clinician or genetic counselor should document the exact tumors, ages at diagnosis, pathology reports, imaging distribution, eye findings, hearing history, and family history. A three-generation pedigree can reveal relatives labeled with “acoustic neuroma,” meningioma, spinal tumor, early hearing loss, or an older diagnosis of NF2. When a relative already has a confirmed variant, a targeted familial variant test is usually more direct than beginning with a broad panel.

How NF2 Testing Detects Germline and Mosaic Disease

A comprehensive constitutional test usually begins with sequencing of the coding regions and relevant splice boundaries of NF2. It should also assess exon-level or whole-gene deletions and duplications, because copy-number changes may not be detected by standard sequence analysis alone. Some laboratories use next-generation sequencing panels that include NF2, SMARCB1, LZTR1, and other genes selected for the tumor pattern. The laboratory’s coverage, validation for mosaicism, deletion-and-duplication method, and reportable variant types are as important as the panel’s gene list.

Blood is the usual first sample, and saliva may sometimes be added. Saliva contains blood-derived and epithelial cells, so it is not independent proof of germline status. A variant near 50% allele fraction in a well-performing blood assay supports a heterozygous constitutional result. A much lower fraction may indicate mosaicism, sample mixture, or artifact and may require confirmation in another tissue.

Mosaicism occurs when the disease-causing change arises after fertilization, so only a subset of cells carries it. The earlier the change occurs in development, the more tissues may be involved. A person with mosaic NF2-related schwannomatosis may have the variant in blood at a low fraction, in saliva but not blood, in only certain tumors, or in multiple tumors without a detectable non-tumor signal. Standard tests optimized for variants near 50% allele fraction can miss low-level mosaicism. High-depth sequencing, careful manual review, unique molecular methods, and a lower validated detection threshold can improve sensitivity.

Tumor testing can be decisive. Ideally, the laboratory evaluates well-characterized tumor tissue and, when possible, compares it with blood. A schwannoma or meningioma may show an initiating pathogenic variant plus loss of the remaining normal copy through a second sequence change, deletion, or loss of heterozygosity. Testing two independent tumors is particularly informative. The same pathogenic variant in both tumors supports a shared mosaic origin, whereas completely different NF2 changes in each tumor may be more compatible with separate sporadic events, depending on the full clinical picture.

Specimen quality matters. Archived formalin-fixed tissue may have degraded DNA or artifacts, and tumor-cell fraction can affect detection. Pathology review should confirm that blocks came from distinct tumors. An experienced laboratory can advise which tumor and non-tumor samples are most informative.

A negative first-line test should therefore prompt a method review rather than an automatic conclusion. Questions include whether deletion-and-duplication analysis was performed, whether the assay was validated for low-level mosaic variants, whether the phenotype warrants a broader schwannomatosis panel, and whether one or more tumors are available. A broad genetic panel test may be appropriate when the diagnosis is uncertain, but it can also generate uncertain findings that require disciplined interpretation.

How to Interpret Positive, Negative, and Uncertain Results

A pathogenic or likely pathogenic NF2 variant in blood generally confirms a constitutional molecular diagnosis when it fits the person’s history. This result supports NF2-specific surveillance and allows targeted testing of relatives. The allele fraction can provide a clue about mosaicism but should not be used alone to calculate severity or transmission risk. Laboratories may classify a result as constitutional, suspected mosaic, or indeterminate based on the measured fraction, assay performance, and confirmation in other samples.

A pathogenic variant found at low level in blood or another non-tumor tissue can establish mosaic disease. The report should state the approximate allele fraction and assay limitations. That percentage reflects the tested sample, not the percentage of the entire body involved. It cannot directly tell how many nerve, eye, reproductive, or brain cells carry the variant. Clinical surveillance is based on the diagnosis and observed manifestations, not solely on the measured fraction.

A pathogenic variant found in one tumor only may be a somatic result restricted to that tumor. It does not by itself prove that the person has NF2-related schwannomatosis or that children and siblings are at increased risk. Interpretation changes if the same variant is present in a second independent tumor or a non-tumor specimen. Reports should clearly separate tumor-level implications from constitutional implications.

A negative blood test lowers the chance of a readily detectable constitutional NF2 variant but does not eliminate mosaic disease. Its meaning depends on the clinical presentation and assay. In a person with bilateral vestibular schwannomas or a highly characteristic tumor pattern, a negative result may lead to high-depth reanalysis, deletion-and-duplication review, tumor testing, or testing for another schwannomatosis gene. In an older adult with one unilateral vestibular schwannoma and no other features, a negative result may be more reassuring because sporadic tumors are common.

A variant of uncertain significance, or VUS, means available evidence is insufficient to classify the change as disease-causing or benign. A VUS should not be used by itself to diagnose NF2-related schwannomatosis, direct irreversible treatment, or test healthy relatives as though the result were predictive. Useful evidence may include population frequency, RNA studies, tumor loss of the normal allele, segregation in relatives, independent clinical observations, and expert laboratory review. General principles for a pathogenic, benign, or VUS result apply, but tumor data and mosaicism give NF2 interpretation additional complexity.

A benign or likely benign variant is not considered an explanation for the condition. Reports may omit common benign findings. Occasionally, a previously uncertain variant is reclassified as evidence accumulates. Patients should know which clinic or laboratory is responsible for recontact and should update the team if new tumors, family diagnoses, or pathology results become available.

Distinguishing NF2 From Other Schwannomatosis Conditions

Multiple schwannomas are not exclusive to NF2. Pathogenic variants in SMARCB1 and LZTR1 cause other schwannomatosis subtypes, and some people have schwannomatosis that remains genetically unclassified. The 2022 international nomenclature names these disorders by the associated gene when known: NF2-related, SMARCB1-related, or LZTR1-related schwannomatosis. The updated language reduces the risk of treating all schwannoma-predisposition conditions as one disease.

NF2-related schwannomatosis is particularly associated with bilateral vestibular schwannomas, meningiomas, ependymomas, and ocular findings. SMARCB1-related and LZTR1-related schwannomatosis more often present with peripheral or spinal schwannomas and pain. Meningiomas can occur in SMARCB1-related disease, while bilateral vestibular schwannomas strongly favor NF2-related disease. A unilateral vestibular schwannoma can occur sporadically or in LZTR1-related schwannomatosis, so age, additional tumors, and molecular findings matter.

Tumor sequencing requires the same distinction. Somatic NF2 inactivation is frequent in sporadic schwannomas and meningiomas. In LZTR1- or SMARCB1-related tumors, chromosome 22 events may also lead to loss of NF2 within the tumor as part of a multi-step mechanism. Therefore, finding an NF2 change in a schwannoma does not necessarily make NF2-related schwannomatosis the constitutional diagnosis. Matched blood testing and comparison across tumors help identify the initiating event.

Other differentials depend on the presentation. Multiple meningiomas can reflect another predisposition syndrome, prior radiation, or a non-inherited pattern. Isolated hearing loss has many non-NF2 causes. Café-au-lait macules with cutaneous neurofibromas instead suggest evaluation for NF1.

This is why “panel positive” is not a complete interpretation. The clinician must identify which gene is altered, whether the variant is constitutional or tumor-limited, whether it is pathogenic, which manifestations are established for that gene, and whether the person meets clinical criteria. The result should lead to a condition-specific plan rather than a generic brain-tumor screening schedule.

Surveillance After an NF2 Diagnosis

Surveillance is intended to detect changes while hearing, neurologic function, vision, and treatment options can still be preserved. Care is best coordinated through a multidisciplinary center familiar with NF2-related schwannomatosis. The team may include medical genetics, neurology, neuro-otology, audiology, neurosurgery, neuro-oncology, ophthalmology, neuroradiology, rehabilitation, pain care, and psychosocial support.

Brain MRI is used to monitor vestibular schwannomas, meningiomas, and other intracranial tumors. Spine MRI assesses ependymomas, schwannomas, and other spinal lesions. The interval depends on age, known tumor burden, prior growth, symptoms, treatment history, and local expert guidance. A newly diagnosed person often needs baseline brain and spine imaging, followed by regular serial studies. Someone with a growing tumor or new symptoms may need shorter intervals than a stable individual. Using the same imaging protocol and comparing measurements over time improves decision-making.

Hearing assessment is central. Pure-tone audiometry and speech discrimination testing can show functional change that tumor size alone does not capture. Auditory brainstem response or other specialized tests may be useful in selected patients. People should report new tinnitus, muffled hearing, difficulty understanding speech, imbalance, facial weakness, or facial numbness rather than waiting for a routine visit. Communication planning, hearing technology, and education or workplace accommodations should begin before hearing loss becomes profound.

Regular eye examination can identify cataracts, retinal findings, or visual consequences of tumors. In children, an ophthalmologic clue may precede the classic vestibular tumor pattern. Neurologic examination should assess cranial nerves, strength, sensation, gait, coordination, and signs of spinal cord or peripheral nerve involvement. Skin examination can document cutaneous schwannomas that may be useful clinically or for tissue analysis.

Urgent evaluation is appropriate for sudden or rapidly worsening hearing, new facial weakness, severe disequilibrium, progressive limb weakness, altered gait, bowel or bladder dysfunction, new seizures, major visual change, or severe headache with neurologic symptoms. These findings can reflect tumor growth, edema, hydrocephalus, spinal compression, or another condition requiring prompt assessment.

Surveillance also addresses treatment effects. Surgery may affect balance, swallowing, or facial movement, while bevacizumab requires blood-pressure, urine-protein, bleeding, and wound-healing monitoring. Psychological support can help with scan anxiety, hearing loss, visible deficits, and family risk.

How Results Influence Treatment and Hearing Care

An NF2 result does not dictate one treatment. Management is based on symptoms, hearing status, tumor growth, tumor location, age, prior procedures, and the function at risk. Small stable tumors may be observed. Surgery may be considered for growing or symptomatic tumors, but the goal is not simply maximal removal; preserving hearing, facial nerve function, spinal cord function, and quality of life may be more important than removing every visible lesion.

Vestibular schwannoma decisions require coordinated hearing planning. Options can include observation, microsurgery, systemic therapy in selected cases, hearing aids, cochlear implantation when the cochlear nerve remains functional, or an auditory brainstem implant when cochlear nerve function cannot support a cochlear implant. Timing matters. A hearing-preservation strategy should be discussed before surgery or before both sides become severely affected.

Bevacizumab, a medicine that inhibits vascular endothelial growth factor, can reduce tumor volume or improve or stabilize hearing in some people with progressive NF2-associated vestibular schwannomas. It is not beneficial for everyone, responses may not be permanent, and adverse effects can limit treatment. Selection and monitoring belong in an experienced NF2 program. A genetic diagnosis can support eligibility and clarify the overall syndrome, but treatment is still guided by measurable clinical need.

Radiation requires particular caution. Evidence indicates that people with NF2-related schwannomatosis have an increased long-term risk of malignancy or malignant progression after radiotherapy to benign tumors. Radiation is therefore generally not treated as a routine first-line solution when safer effective alternatives exist. In difficult cases it may still be discussed, but the conversation should address age, tumor behavior, prior treatments, expected benefit, and the possibility of later radiation-associated harm.

Meningiomas, spinal tumors, and peripheral schwannomas each require site-specific judgment. A spinal lesion that threatens the cord may need intervention even if it is small, while a larger asymptomatic peripheral tumor may be observed. Pain can come from tumor compression, neuropathy, musculoskeletal compensation, or prior surgery and may need a combined neurologic, surgical, rehabilitation, and pain-management approach.

Genotype may inform broad expectations but cannot predict whether a particular tumor will grow. Decisions should remain anchored in hearing trajectory, neurologic examination, imaging, personal goals, and cumulative treatment burden.

Family Testing, Inheritance, and Reproductive Options

Constitutional NF2-related schwannomatosis follows an autosomal dominant inheritance pattern. A person with a heterozygous pathogenic variant present in the germline generally has a 50% chance of passing that variant to each child. The child who inherits it may have a different age of onset, tumor burden, or hearing outcome from the parent. An overview of autosomal dominant inheritance can help families understand why each pregnancy is an independent event.

Many people diagnosed without an affected parent have a de novo variant, and a substantial portion of these individuals are mosaic. Mosaicism changes risk counseling. The chance of transmission is often lower than 50%, but it is not zero because reproductive cells may carry the variant even when blood testing is negative or shows a very low fraction. The exact probability usually cannot be calculated from blood allele fraction. If a mosaic parent transmits the variant, the child may carry it constitutionally in all cells and can have a more extensive phenotype than the parent.

Once the familial pathogenic variant is known, adult relatives can have targeted testing. A relative who tests positive should enter an age-appropriate surveillance program even if asymptomatic. A relative who tests negative for a clearly established familial constitutional variant is usually not considered to have inherited that family’s risk and may avoid repeated NF2 surveillance, unless personal findings require separate evaluation. In mosaic families, testing strategy may need extra care because the proband’s variant might be detectable only in tumor tissue.

Testing children is generally considered when a familial pathogenic variant is known because early identification can change medical care. Families should discuss the age at which hearing tests, eye examinations, neurologic assessment, and imaging will begin. The conversation should also prepare the child in an age-appropriate way and protect privacy while ensuring schools and caregivers understand any hearing or neurologic needs.

Reproductive options may include natural conception with or without prenatal diagnosis, in vitro fertilization with preimplantation genetic testing for monogenic disease, use of donor egg or sperm, adoption, or deciding not to pursue testing. PGT-M requires a clearly characterized familial variant and advance laboratory planning. Chorionic villus sampling or amniocentesis can test a pregnancy for the known variant, but prenatal results usually cannot predict the future number, location, or severity of tumors.

A genetics visit is most productive when the family brings the full laboratory report, tumor pathology, imaging summaries, and records from affected relatives. Useful questions include whether the result is germline, mosaic, or tumor-only; what the assay could miss; whether another tumor should be tested; which relatives should be offered testing; when surveillance should start; and how the result affects reproductive risk. The most accurate plan joins molecular evidence with the individual’s clinical pattern rather than treating either one in isolation.

References

1. Evans DG. NF2-Related Schwannomatosis. GeneReviews®, updated 2023. Clinical review and management resource.
2. Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine, 2022. International consensus guideline.
3. Evans DGR, Salvador H, Chang VY, et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 2 and related disorders. Clinical Cancer Research, 2022. Expert surveillance review.
4. Douwes JPJ, Hensen EF, Jansen JC, Gelderblom H, Schopman JE. Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Systematic Review. Cancers, 2024. Systematic review.
5. Evans DGR, Halliday D, Baser ME, et al. Radiation treatment of benign tumors in NF2-related schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy or malignant progression. Neuro-Oncology Advances, 2023. National cohort study.
6. Dhamija R, Plotkin SR, Blakeley JO. LZTR1- and SMARCB1-Related Schwannomatosis. GeneReviews®, updated 2024. Differential diagnosis and management review.

Disclaimer

This article is for general educational purposes and is not a substitute for individualized medical advice, diagnosis, genetic counseling, or treatment. NF2 testing and tumor results can be complex, particularly when mosaicism is possible; decisions should be made with clinicians and laboratories experienced in schwannomatosis. Seek urgent medical care for rapidly worsening neurologic, hearing, balance, vision, or spinal symptoms.